NinePoint Medical, Inc. announced the commercial launch of its proprietary NvisionVLE(TM) Imaging System in the United States. In addition, NinePoint announced the launch of its newly redesigned website, www.ninepointmedical.com. In December 2011, the NvisionVLE Imaging System received 510(k) clearance from the U.S. Food and Drug Administration for use as an imaging tool in the evaluation of human tissue microstructure by providing two-dimensional, cross sectional, real-time depth visualization. Last month, NinePoint received 510(k) clearance to expand the System's indication to include imaging of esophageal tissue microstructure. Originally developed at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH), NinePoint licensed the imaging technology from MGH in 2010 as part of the intellectual property agreement for medical device technology in the hospital's history. The NvisionVLE Imaging System enables physicians and pathologists to endoscopically view real-time, high-resolution, cross sectional images of organs and tissues up to 3mm deep at better than 10 micron resolution.

NinePoint Medical, Inc. announced that it has received an additional 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its NvisionVLE(TM) Imaging System, expanding the system's indication to include imaging of esophageal tissue microstructure. In January 2012, the company announced 510(k) clearance from the FDA to market its NvisionVLE Imaging System for use as an imaging tool in the evaluation of human tissue microstructure by providing two-dimensional, cross sectional, real-time depth visualization.

NinePoint Medical, Inc. Presents at Boston Biotech Conference, Apr-02-2013 03:30 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Charles S. Carignan, Chief Executive Officer, President and Director.